{"id":403,"date":"2025-04-24T09:00:00","date_gmt":"2025-04-24T09:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=403"},"modified":"2025-10-30T05:30:19","modified_gmt":"2025-10-30T05:30:19","slug":"china-bd-2025-qyuns-and-caldera-entered-a-license-for-bispecific-antibody-qx030n","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2025\/403.html","title":{"rendered":"[China BD 2025] Qyuns and Caldera Entered a License for Bispecific Antibody QX030N"},"content":{"rendered":"\n<p>Announced Date: 2025-04-23 (April 23, 2025)<\/p>\n\n\n\n<p>Asset Name: QX030N<\/p>\n\n\n\n<p>Licensor (Seller): Qyuns Therapeutics (China)<\/p>\n\n\n\n<p>Licensee (Buyer): \u00a0Caldera Therapeutics (US, NewCo)<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset Modality: Bispecific antibody (BsAb)<\/p>\n\n\n\n<p>Asset Target:  undisclosed<\/p>\n\n\n\n<p>Potential Indication: immunologic disorders<\/p>\n\n\n\n<p>Current Stage: pre-clinical stage<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Scope of Authority:<\/p>\n\n\n\n<p>Qyuns Therapeutics grants Caldera Therapeutics an exclusive right to develop and commercialize QX030N globally.<\/p>\n\n\n\n<p>Caldera Therapeutics is granted an exclusive, royalty-bearing, transferable, sublicensable right to research, develop, register, manufacture and commercialize QX030N worldwide.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Payment Detail:<\/p>\n\n\n\n<p>Qyuns Therapeutics&nbsp;will receive:<\/p>\n\n\n\n<p>(i) upfront payment of USD$10 million, <\/p>\n\n\n\n<p>(ii) receive approximately 24.88% of the equity interest in Caldera Therapeutics.<\/p>\n\n\n\n<p>(iii) additional payments of up to USD$545 million, subject to the achievement of certain clinical development, regulatory and commercial milestones. <\/p>\n\n\n\n<p>(iv) tiered royalties on net sales from Caldera Therapeutics during a specified time period after the first<br>commercial sales of QX030N.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link:<\/p>\n\n\n\n<p><a href=\"https:\/\/www.hkexnews.hk\/listedco\/listconews\/sehk\/2025\/0424\/2025042400007.pdf\">2025042400007.pdf (hkexnews.hk)<\/a><\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Note:<\/p>\n\n\n\n<p>Chinese Name of Qyuns Therapeutics, \u8343\u4fe1\u751f\u7269<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2025-04-23 (April 23, 2025) Asset Name: QX030N Licensor (Seller): Qyuns Therapeutics (China) Licensee (Buyer): &hellip; <a title=\"[China BD 2025] Qyuns and Caldera Entered a License for Bispecific Antibody QX030N\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2025\/403.html\"><span class=\"screen-reader-text\">[China BD 2025] Qyuns and Caldera Entered a License for Bispecific Antibody QX030N<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,5],"tags":[],"class_list":["post-403","post","type-post","status-publish","format-standard","hentry","category-china-license-out","category-newco"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/403","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=403"}],"version-history":[{"count":1,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/403\/revisions"}],"predecessor-version":[{"id":404,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/403\/revisions\/404"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=403"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=403"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=403"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}